| 标题 |
Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
诺和诺德的Wegovy®在对肥胖和心血管疾病患者的真实世界研究中,与替西帕肽相比,心脏病发作、中风或死亡的风险降低了57%
|
| 网址 | |
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 求助人 | |
| 下载 |